TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3404814

Group type: EXPERIMENTAL
Intervention: Arginine HCl, 250 mg/kg infused over 30 minutes
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Glucagon, 6 ng/kg/min infused over 30 minutes
Number of subjects: 26

Group type: COMPARATOR
Intervention: Indomethacin, 150 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ibuprofen, 800 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no cyclooxygenase inhibitors)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Indomethacin, 150 mg before second infusion of arginine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Arginine infusion
Number of subjects: 26
Study: 31228219

Group type: EXPERIMENTAL
Intervention: Simple dietary advice
Number of subjects: 59

Group type: COMPARATOR
Intervention: Denture care advice (Control)
Number of subjects: 59
Study: 28931532

Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat diet intervention
Number of subjects: 0
Study: 25174863

Group type: EXPERIMENTAL
Intervention: Nasal mometasone
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 21812821

Group type: EXPERIMENTAL
Intervention: RT-WBV
Number of subjects: 32

Group type: COMPARATOR
Intervention: RT
Number of subjects: 32
Study: 21949643

Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Standard antiretroviral therapy (ART)
Number of subjects: 816
Study: 18436905

Group type: EXPERIMENTAL
Intervention: Electronic reminders
Number of subjects: 1922

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1922
Study: 21310502

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT); 39 patients/44 feet, twice per week for 6 treatments
Number of subjects: 77

Group type: COMPARATOR
Intervention: Hyperbaric oxygen therapy (HBOT); 38 patients/40 feet, daily for 20 treatments
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Blood flow perfusion rates
Number of subjects: 77
Study: 15606437

Group type: EXPERIMENTAL
Intervention: Cetirizine at 0.25 mg kg(‐1) twice daily for 18 months
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Levocetirizine 0.125 mg kg(‐1) twice daily
Number of subjects: 343
Study: 12017416

Group type: EXPERIMENTAL
Intervention: FreeStyle meter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original meter
Number of subjects: 0
Study: 9494686

Group type: EXPERIMENTAL
Intervention: Pheromone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 8109769

Group type: EXPERIMENTAL
Intervention: Supraclavicular paravascular approach (Group S; n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Axillary approach (Group A; n = 20)
Number of subjects: 40
Study: 3391881

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg tid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Erythromycin base (EB) 500 mg tid
Number of subjects: 100
Study: 12111127

Group type: EXPERIMENTAL
Intervention: 99mTc-MIBI uptake in responders
Number of subjects: 37

Group type: COMPARATOR
Intervention: 99mTc-MIBI uptake in non-responders
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Survival rate correlation with ER
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Survival rate correlation with DR
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Survival for patients with ER > 3
Number of subjects: 37

Group type: COMPARATOR
Intervention: Survival for patients with ER < 3
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Survival for patients with DR > 3
Number of subjects: 37

Group type: COMPARATOR
Intervention: Survival for patients with DR < 3
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Survival for patients with Pgp score +2
Number of subjects: 37

Group type: COMPARATOR
Intervention: Survival for patients with Pgp score +1
Number of subjects: 37

Group type: COMPARATOR
Intervention: Survival for patients with Pgp score -
Number of subjects: 37
Study: 31371795

Group type: EXPERIMENTAL
Intervention: SQ-LNS-plus
Number of subjects: 750

Group type: COMPARATOR
Intervention: SQ-LNS
Number of subjects: 750
Study: 29625591

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) with an age-appropriate stimulation program, updated at 3 monthly intervals through the first year of life.
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV-exposed uninfected children (HEU) not having received the stimulatory intervention.
Number of subjects: 0
Study: 26517283

Group type: EXPERIMENTAL
Intervention: High-dose (HD) factor VIII (200 IU kg‐1 day‐1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-dose (LD) factor VIII (50 IU kg‐1 3× per week)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Thrombin generation assay (TGA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Anti-FVIII <1.0 BU
Number of subjects: 31
Study: 25288176

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 0
Study: 22168137

Group type: EXPERIMENTAL
Intervention: Weekly TM-based feedback with goal setting
Number of subjects: 45

Group type: COMPARATOR
Intervention: Weekly TM-based drinking assessments without feedback
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 19660970

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Discontinuation of Hormone Replacement Therapy (HRT)
Number of subjects: 26
Study: 18535251

Group type: EXPERIMENTAL
Intervention: Low magnitudes of torque applied to the knee (0 to 10 N.m varus/valgus, 0 to 5 N.m internal/external)
Number of subjects: 20
Study: 16133153

Group type: EXPERIMENTAL
Intervention: Varus gonarthrosis group
Number of subjects: 75

Group type: COMPARATOR
Intervention: Valgus gonarthrosis group
Number of subjects: 75
Study: 12005463

Group type: EXPERIMENTAL
Intervention: Elemental formula (EF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polymeric immune‐enhancing formula (PIEF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dextrose (control)
Number of subjects: 0
Study: 9927002

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (500 mg, 2 times a day for 48 h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study: 8678250

Group type: EXPERIMENTAL
Intervention: Limited intentional normovolaemic haemodilution to a haematocrit of 34% (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intentional normovolaemic haemodilution (Group B)
Number of subjects: 30
Study: 2128590

Group type: EXPERIMENTAL
Intervention: Pall BB 22 15 filters
Number of subjects: 3

Group type: COMPARATOR
Intervention: Changing anesthetic circuits after every patient
Number of subjects: 3
Study: 342594

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene) 300 mg per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31818835

Group type: EXPERIMENTAL
Intervention: Customised Appropriateness Evaluation Protocol (AEP) for evaluating hospitalisations
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Customised Appropriateness Evaluation Protocol (AEP) for evaluating duration of hospitalisations
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Expert evaluations using the customised AEP
Number of subjects: 1181
Study: 28479852

Group type: EXPERIMENTAL
Intervention: DWP05195 (10-600 mg single dose; 100-400 mg once daily for 8 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DWP05195 (multiple doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DWP05195 (up to 600 mg single dose; 400 mg multiple dose)
Number of subjects: 10
Study: 25919553

Group type: EXPERIMENTAL
Intervention: HFOV combined with pulmonary surfactant (PS)
Number of subjects: 122

Group type: COMPARATOR
Intervention: HFOV alone
Number of subjects: 122
Study: 23203754

Group type: EXPERIMENTAL
Intervention: Success-adapted computer intervention (CogmedRM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-adaptive, active control condition
Number of subjects: 20
Study: 20701549

Group type: EXPERIMENTAL
Intervention: Micronutrient fortification in breakfast maize-porridge for 52 school days
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo powder in breakfast maize-porridge for 52 school days
Number of subjects: 151
Study: 19384179

Group type: EXPERIMENTAL
Intervention: De novo sirolimus-based therapy without calcineurin inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial use of a calcineurin inhibitor for 2 to 4 months followed by conversion to sirolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delaying the introduction of sirolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late withdrawal of steroids
Number of subjects: 0
Study: 16924997

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study: 14598251

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with Photofrin 2 mg/kg body weight, administered intravenously 2 days before intraluminal photoactivation (wavelength, 630 nm; light dose, 180 J/cm²)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Stenting alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 39
Study: 10672082

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 8986544

Group type: EXPERIMENTAL
Intervention: Transmandibular implant (TMI) with a triple bar and cantilever extensions, provided with an overdenture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramobile cylinder implants (IMZ) connected by a Dolder bar, provided with an overdenture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall complication scale
Number of subjects: 0
Study: 1729935

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms/kg lozenge 45 min preoperatively and placebo intravenously after induction
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms/kg lozenge 45 min preoperatively and droperidol 50 micrograms/kg intravenously after induction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo lozenge 45 min preoperatively and placebo (normal saline) injected intravenously after induction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo lozenge 45 min preoperatively and droperidol 50 micrograms/kg intravenously after induction
Number of subjects: 100
Study: 6531960

Group type: EXPERIMENTAL
Intervention: Clone PXH107 (reassortant virus)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clone PX62 (non-reassortant virus)
Number of subjects: 60
Study: 31510950

Group type: EXPERIMENTAL
Intervention: Access to door to door solid waste collection service
Number of subjects: 413

Group type: COMPARATOR
Intervention: Improper solid waste management practices
Number of subjects: 413
Study: 29278428

Group type: EXPERIMENTAL
Intervention: Standard medical therapy (SMT) plus G‐CSF 3 monthly plus GH daily (group A; n = 23)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Standard medical therapy (SMT) plus G‐CSF (group B; n = 21)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard medical therapy alone (group C; n = 21)
Number of subjects: 65
Study: 26991619

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion (initial bolus of 0.25 μg/kg and infusion of 0.25 μg/kg/min)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Leg wrapping
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 112
Study: 24247587

Group type: EXPERIMENTAL
Intervention: MSCs
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: BMCs
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (for MSCs)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (for BMCs)
Number of subjects: 65
Study: 22464501

Group type: EXPERIMENTAL
Intervention: Amitraz odour
Number of subjects: 23

Group type: COMPARATOR
Intervention: Organophosphate odour
Number of subjects: 23
Study: 20346565

Group type: EXPERIMENTAL
Intervention: Bioadhesive 0.2% CHX gel applied intraoperatively once after surgical removal of the third molar
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo gel applied in an identical fashion
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bioadhesive 0.2% CHX gel
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 38
Study: 17634013

Group type: EXPERIMENTAL
Intervention: Pentasaccharide (PS) long-term
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Pentasaccharide (PS) short-term
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 146
Study: 16259543

Group type: EXPERIMENTAL
Intervention: Olanzapine (6-12 mg/day) plus fluoxetine (25-50 mg/day) combination
Number of subjects: 500

Group type: COMPARATOR
Intervention: Olanzapine (6-12 mg/day)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Fluoxetine (25-50 mg/day)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Nortriptyline (25-175 mg/day)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (subgroup analysis)
Number of subjects: 500
Study: 12169040

Group type: EXPERIMENTAL
Intervention: Desloratadine 5mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desloratadine 7.5mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desloratadine 10mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desloratadine 20mg
Number of subjects: 20
Study: 9681726

Group type: EXPERIMENTAL
Intervention: s.c. rHuEpo
Number of subjects: 30

Group type: COMPARATOR
Intervention: i.v. rHuEpo
Number of subjects: 30
Study: 8018527

Group type: EXPERIMENTAL
Intervention: Formestane 250 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Formestane 500 mg
Number of subjects: 143
Study: 2572699

Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard psychomotor testing
Number of subjects: 0
Study: 782888

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (OHP) administered at 2.5 ATA in one or several series of daily exposure.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapy (control group).
Number of subjects: 60
Study: 30633417

Group type: EXPERIMENTAL
Intervention: Crew Resource Management team training intervention
Number of subjects: 8123
Study: 28597005

Group type: EXPERIMENTAL
Intervention: Modified phosphoric acid with chlorhexidine (CHX)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Modified phosphoric acid with benzalkonium chloride (BAC)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Modified phosphoric acid with proanthocyanidins (PRO)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional phosphoric acid (CON)
Number of subjects: 28
Study: 25652442

Group type: EXPERIMENTAL
Intervention: Clinical vignettes
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standardized patients (unannounced visits)
Number of subjects: 59
Study: 25076759

Group type: EXPERIMENTAL
Intervention: Cytoflavin included in intensive care (administered intravenously at a speed of 140 drops (7 ml) per minute within 7 days, starting from the second day post-injury).
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard intensive care without cytoflavin.
Number of subjects: 101
Study: 23057058

Group type: EXPERIMENTAL
Intervention: rhPDGF-BB + β-TCP
Number of subjects: 18

Group type: COMPARATOR
Intervention: HA + β-TCP
Number of subjects: 18
Study: 19097740

Group type: EXPERIMENTAL
Intervention: Self-regulation (SR) weight reduction intervention
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard care with self-help manual
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard care without self-help manual
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Self-regulation (SR) skills
Number of subjects: 53
Study: 17574897

Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 487

Group type: COMPARATOR
Intervention: Dorsal position
Number of subjects: 487
Study: 15352968

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg po 1 h prior to surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (Placebo) + Ketoprofen 100 mg IV q 8 h for 24 h
Number of subjects: 70
Study: 11203774

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2/Clearfil AP‐X (Group I, n = 10)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Resulcin AquaPrime + Monobond/MFR Merz (Group II, n = 9)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Prime&Bond 2.1/Dyract AP (Group III, n = 9)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose/Z‐100 (Group IV, n = 10)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ecusit Primer AB‐Mono/Ecusit (Group V, n = 9)
Number of subjects: 47
Study: 9668369

Group type: EXPERIMENTAL
Intervention: GM1 ganglioside treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8115195

Group type: EXPERIMENTAL
Intervention: 1 mg/kg meperidine
Number of subjects: 84

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 84
Study: 3136636

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Class IC agents (overall)
Number of subjects: 33
Study: 1749015

Group type: EXPERIMENTAL
Intervention: Comprehensive smoking control intervention
Number of subjects: 200000

Group type: COMPARATOR
Intervention: Comparison conditions (control group)
Number of subjects: 200000
Study: 793706

Group type: EXPERIMENTAL
Intervention: Azathioprine, 2.5 mg/kg-d
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31142536

Group type: EXPERIMENTAL
Intervention: Standard action plan
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Literacy-sensitive action plan
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Random allocation
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Allocation by health literacy screening tool
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Allocation by participant selection
Number of subjects: 2400
Study: 28923573

Group type: EXPERIMENTAL
Intervention: Buparlisib plus trastuzumab and paclitaxel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and paclitaxel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Buparlisib plus trastuzumab and paclitaxel (ER+ subgroup)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and paclitaxel (ER+ subgroup)
Number of subjects: 50
Study: 25885054

Group type: EXPERIMENTAL
Intervention: Tunnelled central venous catheter (TCVC) ± autologous arteriovenous fistula (AVF)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Early cannulation synthetic arteriovenous grafts (ecAVG) ± autologous arteriovenous fistula (AVF)
Number of subjects: 118
Study: 24257457

Group type: EXPERIMENTAL
Intervention: LMA Unique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Air-Q
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CobraPLA
Number of subjects: 30
Study: 21784378

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg added to Simvastatin 40 mg (E/S40)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg (A)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5-10 mg (R)
Number of subjects: 786
Study: 19410356

Group type: EXPERIMENTAL
Intervention: Animation-assisted CPRII (AA-CPRII) instruction on cellular phones
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no additional instruction)
Number of subjects: 80
Study: 17507190

Group type: EXPERIMENTAL
Intervention: Sustained-release nifedipine tablets from DiSha (test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sustained-release nifedipine tablets from GuoFeng (reference)
Number of subjects: 20
Study: 15208493

Group type: EXPERIMENTAL
Intervention: 201Tl gated single photon emission computed tomographic (201Tl GSPECT) myocardial perfusion imaging
Number of subjects: 172

Group type: COMPARATOR
Intervention: Equilibrium radionuclide angiography (ERNA)
Number of subjects: 172
Study: 15487693

Group type: EXPERIMENTAL
Intervention: Light panretinal photocoagulation (LPRP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Classic panretinal photocoagulation (CPRP)
Number of subjects: 50
Study: 10024902

Group type: EXPERIMENTAL
Intervention: Continuous combined HRT (2 mg 17 beta‐estradiol and 1 mg norethisterone acetate administered once daily without estriol)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Continuous combined HRT
Number of subjects: 27
Study: 8002124

Group type: EXPERIMENTAL
Intervention: GP/PL mixture (6.25 g GP to 0.75 g PL per 100 ml of water)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Glucose polymer solution (GP)
Number of subjects: 5
Study: 3190813

Group type: EXPERIMENTAL
Intervention: Euphylong pellets
Number of subjects: 168
Study: 30498758

Group type: EXPERIMENTAL
Intervention: Curene 500 mg once daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 27465859

Group type: EXPERIMENTAL
Intervention: Aspirin users (32 patients)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo group (38 patients)
Number of subjects: 70
Study: 24447886

Group type: EXPERIMENTAL
Intervention: Web-based health promotion program
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 22090466

Group type: EXPERIMENTAL
Intervention: Elastic Stocking (ES) exerting a pressure of 23-32 mmHg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inelastic Bandage (IB) exerting a high pressure
Number of subjects: 30
Study: 20718226

Group type: EXPERIMENTAL
Intervention: Cooperative learning in pairs
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cooperative learning in groups of 4
Number of subjects: 62

Group type: COMPARATOR
Intervention: Individualistic learning
Number of subjects: 62
Study: 18630533

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with western medicine (acupuncture at specific points, intramuscular injection of Vit B1 and Vit B12, oral administration of ATP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Simple western medicine
Number of subjects: 90
Study: 16046716

Group type: EXPERIMENTAL
Intervention: Lyophilized grape powder (LGP) 36 g for 4 weeks
Number of subjects: 44